Zhang Guowei, Wang Huijuan, Ma Zhiyong
Department of Internal Medicine, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Zhongguo Fei Ai Za Zhi. 2017 Apr 20;20(4):278-286. doi: 10.3779/j.issn.1009-3419.2017.04.09.
At present the treatment of advanced non-small cell lung cancer enters a targeted era and develops rapidly. New drugs appear constantly. Small molecular tyrosine kinase inhibitors have occupied the biggest piece of the territory, which commonly have a clear biomarker as predictor, and show remarkable effect in specific molecular classification of patients. The epidermal growth factor tyrosine kinase inhibitors such as gefitinib, erlotinib, icotinib and anaplastic lymphoma kinase tyrosine kinase inhibitors crizotinib have brought a milestone advance. In recent years new generations of tyrosine kinase inhibitors have achieved a great success in patients with acquired resistance to the above two kinds of drugs. At the same time new therapeutic targets are constantly emerging. So in this paper, we reviewed and summarized the important drugs and clinical trails on this topic, and made a prospect of the future development.
目前，晚期非小细胞肺癌的治疗进入了靶向治疗时代并迅速发展。新药不断涌现。小分子酪氨酸激酶抑制剂占据了最大的市场份额，这类药物通常有明确的生物标志物作为预测指标，在特定分子分型的患者中显示出显著疗效。表皮生长因子酪氨酸激酶抑制剂如吉非替尼、厄洛替尼、埃克替尼以及间变性淋巴瘤激酶酪氨酸激酶抑制剂克唑替尼带来了里程碑式的进展。近年来，新一代酪氨酸激酶抑制剂在对上述两类药物产生获得性耐药的患者中取得了巨大成功。同时，新的治疗靶点也不断涌现。因此，本文对该领域的重要药物和临床试验进行了综述和总结，并对未来发展进行了展望。
